Venlafaxine - Depression
You are here : Home > Formulary Search > Venlafaxine - Depression
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Status 2
Green (see narrative)
Formulations :
- Modified release capsules
- Modified release tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
In Primary Care, OptimiseRx will be used to recommend the most cost-effective formulation at the point of prescribing.
Documentation
PAD Profile
ChemicalSubstance :
Venlafaxine
Indication :
Depression
Group Name :
Keywords :
Brand Names Include :
Efexor XL, Sunveniz XL, Venladex XL, Venaxx, Depefex, Venlalic, Vensir XL, ViePax XL, Vencarm XL,
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2
Other Indications
Below are listed other indications that Venlafaxine is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Depression.
- Amitriptyline hydrochloride
- Bupropion hydrochloride
- Citalopram
- Clomipramine hydrochloride
- Duloxetine hydrochloride
- Esketamine hydrochloride
- Fluoxetine hydrochloride
- Fluvoxamine maleate
- Imipramine hydrochloride
- Isocarboxazid
- Lithium - adults
- Lofepramine hydrochloride
- Mianserin hydrochloride
- Mirtazapine
- Moclobemide
- Nortriptyline
- Paroxetine hydrochloride
- Phenelzine sulfate
- Quetiapine
- Reboxetine
- Sertraline
- Tranylcypromine sulfate
- Trimipramine maleate
- Vortioxetine
Committee Recommendations (1)
15 Aug 18 -
Not Set
The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD. Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries.